| 摘要 |
New topically applied compositions (A) contain 5-aminosulfonyl-2-phenylacetamido-thiazole derivatives (I) at 0.1-99 wt. %. New topically applied compositions (A) contain thiazole derivatives of formula (I) or their salts at 0.1-99 wt. %. [Image] R 1H, halo, alkyl, alkoxy, aminoalkyl or haloalkyl; R 2, R 3H, alkoxy, 3-5C cycloalkyl or biphenylaminocarbonyl; alkyl (optionally substituted (os) by 1-3 of 3-6C cycloalkyl, alkoxy, halo, OH, NH 2, trialkylsilyloxy, 3,4-methylenedioxyphenyl, tetrahydrofuran-2-yl, -N(R' 2)COOtBu, Het 1, Het 2 or aryl (os by OH or alkoxy)); -P(O)(OR 8)(OR 9), -COCH(NH 2)-R 1 0, -CHR 1 1-OCOR 1 2 or -CH(NH 2)-R 1 0; or NR 2R 35- or 6-membered saturated heterocycle, optionally containing a further O heteroatom; R' 2, R 8, R 9H or 1-4C alkyl; Het 1C- or N-bonded 5- or 6-membered aromatic heterocycle containing 1-3 of S, N and/or O as heteroatom(s)); Het 2C- or N-bonded 3-8 membered, saturated or unsaturated, non-aromatic heterocycle containing 1-3 of S, N and/or O as heteroatom(s)); R 1 0side-chain of a naturally occurring aminoacid; R 1 11-4C alkyl; R 1 2H, 1-4C alkyl or -CH(NH 2)-R 1 0; R 4H, acyl, 2-6C alkenyl or cycloalkyl; or alkyl (os by 1-3 of halo, OH, cycloalkyl, acyl, alkoxy, COOH, NHCOOtBu, OEt, -CH 2CH 2OEt, phenoxy, aryl or NR 1 3R 1 4); or alkyl substituted by optionally benzo-fused Het 1, 2-(R 1 6)-pyrrolidino, tetrahydrofuran-2-yl, benzo-1,4-dioxan-2-yl, 2-oxo-pyrrolidino or -OCOR 1 7R 1 8; R 1 3, R 1 4H, acyl, alkyl, CONH 2, mono- or dialkylaminoalkyl, mono- or dialkylaminocarbonyl, aryl or alkoxycarbonyl; or NR 1 3R 1 45- or 6-membered saturated heterocyclyl, optionally containing a further O, S or NR 1 5 heteroatom and os by =O; R 1 5H or 1-4C alkyl; R 1 6H or alkyl; R 1 7, R 1 8H; or alkyl or aryl (both os by 1-3 of OH, alkoxy or halo); R 5, R 7H, alkyl, halo, NH 2, mono- or dialkylamino or alkanoylamino; R 6phenyl (os by 1-3 groups R' 6); R' 6halo, aryl (os by 1-3 of alkanoyl, alkoxy, alkyl, halo, alkoxycarbonyl, NO 2, haloalkyl, haloalkoxy, NH 2, alkylthio, OH, COOH, CONH 2, mono- or dialkylaminocarbonyl, mono- or dialkanoylamino, alkoxycarbonylamino, alkylsulfoxy, alkylsulfonyl, trialkylsilyloxy, Het 2 or CN), alkoxy (os by 1-6 F, but not perfluorinated), alkoxycarbonyl, alkylthio, OH, COOH, alkyl (os by tetrahydrofuran-2-yl), Het 1 (os by 1-3 of alkanoyl, alkoxy, alkyl, halo, alkoxycarbonyl, NO 2, haloalkyl, haloalkoxy, NH 2, alkylthio, OH, COOH, CONH 2, mono- or dialkylaminocarbonyl, mono- or dialkanoylamino, alkoxycarbonylamino, alkylsulfoxy, alkylsulfonyl, Het 2 (mono- or bicyclic) or CN), Het 2 (mono- or bicyclic; and os by 1-3 of =O, halo, OH, alkoxycarbonyl, alkoxycarbonylamino, alkyl, haloalkyl or hydroxyalkyl), 2-6C alkenyl, OR 1 9, NR 2 0R 2 1, CONR 2 2R 2 3, carbazole, dibenzofuran, dibenzothiophene, xanthene or 9,10-dihydroacridine; R 1 9phenyl (os by NR 2 4R 2 5) or alkyl (os by 1-3 of OH or halo); R 2 4, R 2 5H, alkyl or acyl; R 2 0, R 2 1H, CONH 2, mono- or dialkylaminocarbonyl, phenyl, acyl or alkyl (os by alkoxy or acyl; or by phenyl or Het 1 (both os by 1-3 of halo or OH)); R 2 2, R 2 3H or alkyl; alkyl moieties or acyl groups have 1-6C, cycloalkyl moieties 3-8C and aryl moieties 6-10C unless specified otherwise. ACTIVITY : Virucide; ophthalmological. In an ocular herpes model in mice infected with HSV-1, the number of mice surviving on day 16 was 10/10 for mice treated 5 times daily with eye-drops containing N-(5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl)-N-methyl-2-(4-(2-pyridinyl)-phenyl)-acetamide (Ia), 7/10 after treatment with acyclovir and 0/0 after placebo treatment. MECHANISM OF ACTION : None given in the source material. |
